Clinical stage · CNS · Low-risk development
Serotune's product candidates are a capital-efficient opportunity to bring a clinically validated, regulatory-supported therapy for chronic pain and fatigue-related disorders to market quickly.
Investment highlights
Known active substances, human efficacy data already in hand and encouraging regulatory feedback – six reasons why this programme carries less risk than a new chemical entity.
Data available from two clinical studies in patients.
Addresses central serotonin deficiency – so far not adequately treated.
Repurposing lowers development risk and capital requirements.
A capital-efficient path to substantial value creation – clinically validated, regulatory-supported and close to market.
Clinical studies
Core indications
Product candidates
Therapeutics
A de-risked, clinical-stage repurposing asset addressing substantial unmet need in global markets – across several disorders with central serotonin deficiency.
Strong biological rationale – central serotonin deficiency, so far not adequately addressed.
Portfolio
Serotonin enhancer
Serotonin and the CNS
A shared pathophysiological mechanism may underlie several chronic disorders. Reduced central serotonin availability maps onto chronic pain, low mood, fatigue and disturbed sleep – a deficiency that today's therapies do not correct at its cause.
Serotonin modulates pain processing, mood, drive and sleep.
Central 5-HT deficiency and the symptom clusters associated with it.
Product concept
The new – and patented – idea is to administer the 5-HT precursors that can cross the blood-brain barrier together with a degradation inhibitor.
The inhibitor raises precursor concentrations at the blood-brain barrier and defuses the pharmacokinetic problems that limit the precursors on their own.
Relevant precursor concentrations thus reach the brain and can correct the central 5-HT deficiency.
Transport of the 5-HT precursors across the blood-brain barrier, with and without a degradation inhibitor.
Indications
Millions of patients live with the debilitating consequences of central 5-HT deficiency – and with inadequate treatment options.
Diagnostics
Compelling clinical data on platelet 5-HT content as a surrogate for disorders with central 5-HT deficiency.
Platelets in peripheral blood and serotonergic neurons in the brain show clear parallels – with respect to:
Morphology
Biochemistry and metabolism of 5-HT
Uptake kinetics at the plasma membrane
Inhibitory effects on 5-HT uptake
Granular 5-HT storage and how other substances interact with it
Receptors on the outer cell membrane
Comparable effects of receptor antagonists and agonists
Team
An experienced team capable of bringing this drug candidate to market quickly.
CEO
30y experience in drug development
Newsletter & contact
Programme updates, regulatory milestones and publications. For enquiries, write to info@serotune.com.
Ser01, Ser02 and T-5HT are investigational products. They are not approved by any regulatory authority, their safety and efficacy have not been established, and they are not available outside clinical studies. The content of this page is not medical advice.
Positive scientific advice from the German BfArM.
Fibromyalgia and chronic pain across a wide range of conditions.
Platelet 5-HT content as a surrogate marker of the central deficiency.
The available human efficacy data are convincing.
Known active substances – low risk of toxicity issues and of difficulties in pharmaceutical development.
Encouraging regulatory feedback from the German BfArM is already in hand.
Large market opportunities across several distinct indications.
Clear unmet medical need in central serotonin deficiency.
Experienced management team able to bring this project to market quickly.
Additional potential from the companion diagnostic.
Next-generation serotonin enhancer
Diagnostic test – platelet 5-HT
Development status per Serotune's portfolio overview, as of August 2026. Bar length indicates progress within the respective phase.
Second indication
Dysfunction of central pain-control systems amplifies pain and lets it persist long after the initial injury.
Further indication
Persistent symptoms after SARS-CoV-2 infection that overlap with ME/CFS, including fatigue, post-exertional symptom exacerbation, cognitive dysfunction and sleep disturbance.
Drafts of the indication pages. Further indications will follow.
Established methods for determining platelet 5-HT content, uptake and release exist – but have so far rarely been used to characterise a central 5-HT deficiency.
Platelets mirror serotonergic neurons in morphology, 5-HT metabolism, uptake and storage.
CSO, Inventor
Neurologist, psychiatrist, psychotherapist and pain specialist
CFO
25y experience in healthcare and financing of start-up companies
SVP Regulatory & PrjMgmt
30y experience in drug development with focus on RegAffairs
Ser01, Ser02 and T-5HT are investigational products. They are not approved by any regulatory authority, their safety and efficacy have not been established, and they are not available outside clinical studies. The information on this website is provided for general and investor-relations purposes. It does not constitute medical advice, a treatment recommendation or an offer to sell securities.
© 2026 Serotune Biosciences GmbH. All rights reserved.
